Compumedics Limited (CMP) AI Stock Analysis

• Market Cap: AU$54.78M
• Dividend Yield: N/A
• Average Volume (3M): 34.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: -5.62%
• EPS Growth: -225.71%
• Country: AU
• Employees: 155
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 192,217,900
• 10 Day Avg. Volume: 11,060
• 30 Day Avg. Volume: 34,731
• PEG Ratio: 0.07
• Price to Book (P/B): 2.47
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -34.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: AU$0.50 ▲(78.57%Upside)

Compumedics Limited's stock score is primarily driven by its financial performance and technical analysis. Positive revenue growth is overshadowed by ongoing profitability issues and negative market momentum. The lack of earnings call insights and corporate events limits further assessment.

Compumedics Limited Business Overview & Revenue Model

Company Description

Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Okti; Grael PSG; Grael DC; Somfit/Somfit Pro, a wearable device; TCM5 FLEX Transcutaneous monitor; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, and persyst software products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.

How the Company Makes Money

Compumedics Limited generates revenue through the sale of its medical devices and software solutions. The company's revenue streams include direct sales to hospitals and clinics, as well as through distributors and partnerships with healthcare providers globally. Compumedics also earns income from ongoing service and support contracts, which involve maintenance and updates for their diagnostic equipment. Additionally, the company invests in research and development to introduce new technologies and stay competitive in the market, which can lead to increased sales and expanded market reach. Strategic collaborations and partnerships further enhance their market presence and contribute to their financial performance.

Compumedics Limited Financial Statement Overview

Summary

Compumedics Limited is showing positive revenue growth and stable gross profit margins, indicating potential for future performance improvements. However, the company faces significant challenges with ongoing net losses, negative EBIT, and negative free cash flow. The balanced capital structure with moderate leverage is a positive aspect, but improving profitability is essential for financial stability.

Income Statement

Compumedics Limited has shown a positive revenue growth rate of 17.23% from 2023 to 2024, indicating a recovery trend. However, the company continues to experience negative net income and EBIT, resulting in negative net and EBIT margins. Gross profit margins have remained relatively stable, suggesting efficient cost management at the gross level but challenges in operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has increased slightly, indicating a moderate level of leverage. The equity ratio stands at 45.11%, which reflects a balanced capital structure but a decrease from previous years. Return on equity remains negative due to net losses, highlighting profitability challenges.

Cash Flow

Compumedics Limited's free cash flow has improved from 2023 to 2024 but remains negative. The operating cash flow to net income ratio is favorable, suggesting that cash flow generation relative to net income is strong. However, the overall negative free cash flow indicates ongoing challenges in generating sufficient cash from operations.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
46.83M	49.72M	42.41M	37.76M	35.74M	35.07M
	Gross Profit
24.12M	26.07M	21.59M	19.32M	19.16M	18.01M
	EBIT
-1.47M	-269.00K	-3.53M	137.00K	398.00K	-756.00K
	EBITDA
551.00K	2.79M	-5.05M	1.35M	2.56M	-5.42M
	Net Income Common Stockholders
-1.75M	-338.00K	-6.12M	1.36M	998.00K	-5.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.96M	1.89M	3.80M	7.29M	6.77M	6.41M
	Total Assets
47.82M	40.36M	41.18M	41.71M	38.55M	35.53M
	Total Debt
12.56M	8.58M	9.47M	6.55M	5.82M	4.80M
	Net Debt
8.59M	6.69M	5.67M	-746.00K	-950.00K	-1.61M
	Total Liabilities
26.43M	22.15M	22.89M	18.12M	16.39M	13.73M
	Stockholders Equity
21.39M	18.21M	18.29M	23.59M	22.16M	21.79M
Cash Flow		Free Cash Flow
-1.57M	-986.00K	-4.36M	302.00K	-230.00K	1.15M
	Operating Cash Flow
-1.30M	2.00M	49.00K	3.29M	1.32M	5.38M
	Investing Cash Flow
-5.95M	-2.99M	-4.41M	-2.98M	-1.55M	-4.23M
	Financing Cash Flow
6.83M	-1.49M	-1.00M	1.61M	-179.00K	448.00K

Compumedics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMP, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.30, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.58 is Neutral, neither overbought nor oversold. The STOCH value of 19.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CMP.

Compumedics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
CMP	50 Neutral	AU$54.78M	―	-8.08%	―	-5.62%	-225.71%
CHEOF		$11.41B	46.62	20.61%	1.61%	―	―
CMXHF		$76.11B	26.67	15.38%	1.85%	―	―
NNCSF		$848.17M	72.50	9.23%	―	―	―
RMD	79 Outperform	AU$56.78B	27.93	25.23%	0.85%	10.54%	38.69%
RHT	61 Neutral	AU$18.38M	140.00	-3.11%	―	89.13%	69.57%

Compumedics Limited Corporate Events

Compumedics Adjusts FY25 Financial Guidance and Confirms FY26 Outlook

Compumedics Limited announced a correction to its financial guidance for FY25, expecting sales orders to exceed $60 million, with reported revenues between $50 million and $55 million, which is below the previously advised $55 million. The company anticipates an EBITDA of about $3 million for FY25, down from the previously advised $5 million. Looking ahead, Compumedics confirms FY26 revenue guidance of at least $70 million, driven by the shipment of MEG orders, with an expected EBITDA of at least $9 million.

Compumedics Secures $1M Somfit Contract with Leading US CRO

Compumedics Limited has secured a significant contract worth $1 million for its Somfit device with a leading pharmaceutical Contract Research Organisation in the USA. This sale is part of Compumedics’ strategy to expand beyond the home sleep testing market into pharmaceutical clinical trials, leveraging Somfit’s ability to directly track brain signals for accurate sleep architecture analysis. The contract highlights the company’s strong growth in the USA, with sales orders reaching $12 million this year, a 130% increase from the previous year. Compumedics anticipates continued growth, projecting sales orders over $60 million for FY25, although revenue and EBITDA expectations have been adjusted due to the rapid business expansion.